Osteoarthritis Painkillers May Resume Trials Despite Joint Damage Risks

U.S. drug regulators may allow companies to restart clinical trials centered on osteoarthritis painkillers that carry a risk of joint damage, according to a Reuters report.

Pfizer, Regeneron Pharmaceuticals and Johnson & Johnson are now proposing to resume the trials, which the FDA suspended in 2010 after nearly 500 study participants needed to have joints replaced.  FDA advisers will vote today on potential options for continuing the trials, including  limiting the drug dosage and administering the drug only to people with fewer treatment options, such as terminal patients with severe bone pain.

Related Articles on Pain Management:

Kentucky House Approves Pain Clinic Regulation Bill
KURE Pain Management in Maryland Welcomes New Pain Specialist
Alabama 2012 Pain Research Symposium to Welcome Diverse Research Panel

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Whitepapers

Featured Podcast